Yiwen Chen

Company: Zensun

Job title: EVP

Seminars:

Neucardin® (rh-Neuregulin-1), A Late Stage First-in-Class Therapeutic Agent for Chronic Heart Failure 10:15 am

A FIC biologic with novel target MoA directly on cardiomyocytes. Multiple trials involving over 2000 HF patients indicated a great potential to significantly reduce mortality and reverse ventricular remodeling in target patients. Under US/China Phase III stage and was granted FDA fast track designation, expected to be commercialized in 2025 at the earliestRead more

day: Day One